Li, Y., Zhou, Y., Wang, Y., Tong, L., Jiang, R., Xiao, L., . . . Wang, X. (2018). Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study. Medicine (Baltimore).
Chicago-stil citatLi, Yi-Hui, et al. "Comparison of Apatinib and Capecitabine (Xeloda) With Capecitabine (Xeloda) in Advanced Triple-negative Breast Cancer As Third-line Therapy: A Retrospective Study." Medicine (Baltimore) 2018.
MLA-referensLi, Yi-Hui, et al. "Comparison of Apatinib and Capecitabine (Xeloda) With Capecitabine (Xeloda) in Advanced Triple-negative Breast Cancer As Third-line Therapy: A Retrospective Study." Medicine (Baltimore) 2018.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.